Contact us
Contact us

Gore Ventures

Internal Ventures

Innovation Approach

Gore’s Internal Ventures group is comprised of wholly-owned, organically derived “startup” teams that leverage lean innovation approaches – where Associates rapidly test, learn and validate or invalidate opportunities for potential commercial success. Validated concepts may become part of an existing Gore business if they fit with their growth strategy, a new commercial business for Gore, or an external venture.

Caution: Investigational device. Limited by US law to investigational uses.

Pursuing a Viable Alternative for Corneal Tissue Transplants

Gore is developing an investigational synthetic cornea device with goal of providing an alternative treatment for corneal opacity - the 4th leading cause of blindness worldwide.1 The soft, transparent fluoropolymer optic combined with a porous, biocompatible expanded PTFE (ePTFE) skirt is intended to restore vision when donor corneas fail.

1 Murthy_GVS, Johnson_GJ. Prevalence, incidence and distribution of visual impairment. In: The Epidemiology of Eye Disease. 3rd ed. Imperial College Press, 2012;1:3-61

Paving the Way for Cleaner Air

Gore’s Structured Direct Air Capture (DAC) Contactor, used in systems that remove carbon dioxide from the atmosphere, minimizes pressure drop and increases steam stability of the sorbent material.

Gore’s composite structures enable and enhance a variety of sorbent technologies, creating scalable solutions to advance DAC technology.

Envisioning the Future of Glaucoma Treatment

Gore is developing an investigational implant intended to treat glaucoma, a condition that damages the optic nerves and can lead to blindness. Often caused by persistent high pressure in the eye, a glaucoma drainage implant reduces the pressure by draining the accumulated fluid. However, with conventional implants, the eye tissue that absorbs the fluid can scar over time, reducing efficacy.

Our porous, biocompatible ePTFE reservoir incorporated in this investigational device is intended to minimize fibrosis a with a goal of improved durability.

Caution: Investigational device. Limited by US law to investigational uses.

Internal Ventures News & Events

What is New in Artificial Corneas

Since the first successful full thickness corneal transplantation was performed by Eduard Zirm in 1905, the procedure has grown to become the most commonly performed transplantation globally.

Read More

GORE Glaucoma Drainage Implant Clinical Study Dominican Republic

The objective of this early feasibility clinical study is to evaluate the safety and effectiveness of the GORE Glaucoma Drainage Implant (2 configurations) in subjects with primary open-angle glaucoma that is uncontrolled by hypotensive medications or for which conventional incisional glaucoma surgery would be more likely to fail due to scarring.

Read More
View All News
Copyright 2024 W. L. Gore & Associates, Inc.

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not “sell” the personal information of website users. Gore may “share” the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-out Of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.